RBC Capital Starts Climb Bio (CLYM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Price: $10.25 -0.77%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
RBC Capital initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.
Shares of Climb Bio closed at $11.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Mondelez International (MDLZ) to Buy
- Google in talks with DoD for work on Golden Dome - Bloomberg
- Freedom Broker Upgrades Garrett Motion (GTX) to Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
